Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

A study found that dogs eating high-carb kibble showed markedly different blood chemistry than those eating a ...

U.S. pharmaceutical giant Eli Lilly (LLY) is acquiring gene therapy developer Adverum Biotechnologies (ADVM) in a deal valued ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...